Castle Biosciences INC Form 4 insider transactions

Castle Biosciences President and CEO Derek Maetzold sold over 44,000 shares of common stock following the exercise of options under a pre-arranged plan.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, reported standard equity compensation activities including RSU vesting, stock acquisitions, and tax-related dispositions.

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, reported recent transactions involving common stock and restricted stock units, including tax withholdings and RSU conversions.

Castle Biosciences' President and CEO, Derek J. Maetzold, reported routine transactions involving common stock and Restricted Stock Units, including tax withholdings and RSU conversions.

Castle Biosciences CFO Frank Stokes reported sales of common stock and the exercise of stock options, alongside new RSU grants, under a pre-arranged 10b5-1 plan.

Castle Biosciences President and CEO Derek J. Maetzold sold 4,017 shares of common stock across three transactions in early February 2026, executed under a pre-arranged 10b5-1 trading plan.

Castle Biosciences President and CEO Derek J. Maetzold sold 4,017 shares of common stock for a weighted-average price of $40.013 per share as part of a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek J. Maetzold acquired 62,219 shares of common stock through the vesting of performance-based units and received an additional 62,219 performance-based stock units.

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, acquired 9,207 shares of common stock through the vesting of performance-based stock units.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, acquired 9,207 shares of common stock and 9,207 performance-based stock units following the vesting of 2024 PSUs.

Castle Biosciences' Chief Financial Officer, Frank Stokes, acquired 8,124 shares of common stock following the vesting of performance-based stock units.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 4,017 shares of common stock in early January 2026 through a pre-arranged 10b5-1 trading plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 830 shares of common stock for a weighted-average price of $40.35 per share under a pre-arranged 10b5-1 plan.

Castle Biosciences President and CEO, Derek J. Maetzold, reported the sale of 509 shares of common stock at a weighted-average price of $40.04 per share under a pre-arranged 10b5-1 plan.

Castle Biosciences' Chief Operating Officer, Kristen M Oelschlager, sold 14,888 shares of common stock for a weighted-average price of $39.313 per share.

Castle Biosciences President and CEO Derek J. Maetzold sold 32,346 shares of common stock in December 2025 through a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, sold 13,200 shares of common stock for approximately $37.48 per share, executed under a Rule 10b5-1 plan.

Castle Biosciences' Chief Financial Officer, Frank Stokes, sold 4,496 shares of common stock for $37.45 per share under a pre-planned trading arrangement.

Castle Biosciences CEO Derek Maetzold reported the vesting of restricted stock units and subsequent acquisition of common stock, alongside tax-related dispositions.

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported the vesting and subsequent sale of company common stock for tax purposes.

Castle Biosciences Chief Financial Officer Frank Stokes acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, exercised Restricted Stock Units and subsequently sold shares for tax withholding purposes.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 1,339 shares of common stock for approximately $40.03 per share under a pre-arranged 10b5-1 plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 2,678 shares of common stock for approximately $39.23 per share under a pre-arranged 10b5-1 plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 4,258 shares of common stock for approximately $40.09 per share under a pre-arranged 10b5-1 trading plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 5,115 shares of common stock for approximately $40.05 per share under a pre-arranged 10b5-1 plan.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, exercised stock options and immediately sold 4,693 shares of common stock for a weighted-average price of $35.58 per share.

Castle Biosciences President and CEO Derek J. Maetzold sold 2,678 shares of common stock for approximately $91,100 under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, filed an amended Form 4 to correct previously omitted stock option exercises and sales.

Castle Biosciences CFO Frank Stokes sold 5,388 shares of common stock for a weighted-average price of $35.08 per share, pursuant to a pre-arranged 10b5-1 plan.